Vyvanse in Hispanic / Latino Patients: Documented Efficacy Gaps and What They Mean for Dosing

Why Ethnicity Matters for Lisdexamfetamine Response

Lisdexamfetamine is a prodrug. It requires enzymatic cleavage in red blood cells to release d-amphetamine, the pharmacologically active moiety. Because that conversion step happens in erythrocytes rather than the liver, classic CYP-enzyme polymorphisms do not directly determine how much d-amphetamine a patient produces from a given dose. The picture is more indirect than that. Downstream clearance of d-amphetamine still involves CYP2D6-mediated oxidation, and CYP2D6 allele frequencies vary meaningfully across ethnic groups.

Beyond enzyme genetics, urinary pH shapes how much amphetamine the kidneys reclaim after filtration. Diets richer in fruits, legumes, and vegetables push urine pH upward, increasing ionization of amphetamine and reducing tubular reabsorption. Dietary patterns differ across populations. These two mechanisms together, differential CYP2D6 activity and variable urinary pH, can produce clinically meaningful swings in steady-state d-amphetamine exposure even when every patient takes an identical 50 mg capsule.

The Prodrug Conversion Step

Red blood cell hydrolysis of lisdexamfetamine to l-lysine and d-amphetamine is considered capacity-unlimited under normal physiologic conditions. Hematocrit, hemoglobin concentration, and erythrocyte enzyme activity all theoretically influence this step. Sickle cell trait, hereditary spherocytosis, and iron-deficiency anemia alter erythrocyte physiology. Hispanic / Latino populations in the United States carry certain hemoglobin variants at higher frequencies than non-Latino white populations, though published data directly linking these to lisdexamfetamine conversion efficiency are lacking as of early 2025.

CYP2D6 Polymorphism Frequencies in Latino Populations

CYP2D6 metabolizes d-amphetamine to less active 4-hydroxyamphetamine. Poor metabolizers accumulate more parent drug per dose. Ultra-rapid metabolizers clear it faster. PharmGKB catalogues CYP2D6 star-allele frequencies by population. The CYP2D6*4 (poor metabolizer) allele appears in roughly 1 to 7% of Latino individuals compared with approximately 12 to 21% of non-Latino white individuals [1]. Conversely, gene duplication alleles that confer ultra-rapid metabolism may be more prevalent in some Latino subgroups, particularly those with high proportions of Indigenous American ancestry [2].

Clinically, a Latino patient who is a CYP2D6 ultra-rapid metabolizer may experience a shorter effective duration of Vyvanse and feel the medication "wears off too quickly" even at doses that work well for average metabolizers. A poor metabolizer in the same ethnic group may accumulate more d-amphetamine, increasing cardiovascular side-effect risk at standard doses.

What the Trial Data Actually Show

Most large lisdexamfetamine RCTs enrolled participants without prospective pharmacogenomic stratification and without powered ethnicity-specific subgroup analyses. That absence of data is itself a clinical finding worth understanding.

Wigal et al. (2017): The Most Relevant Subgroup Analysis

Wigal and colleagues published a post-hoc analysis of pediatric ADHD lisdexamfetamine trial data in the Journal of Attention Disorders (2017) that examined response by racial and ethnic subgroups [3]. The study found that Hispanic / Latino children showed statistically significant ADHD Rating Scale (ADHD-RS-IV) improvements with lisdexamfetamine versus placebo, consistent with the overall trial population. However, effect sizes within the Hispanic / Latino subgroup were numerically smaller than in non-Latino white participants, and confidence intervals were wide enough that the authors could not rule out a clinically meaningful difference in magnitude of response.

That width of confidence intervals is not a minor methodological footnote. It reflects small subgroup sample sizes and points directly to the evidence gap that still exists in 2025.

STEP Trials and Binge Eating Disorder

The FDA approval of lisdexamfetamine for moderate-to-severe binge eating disorder rested on two Phase III trials. McElroy et al. (2015) enrolled 383 adults in one trial and 390 in a second. Combined, Hispanic / Latino participants represented fewer than 15% of enrollees in both studies. Ethnicity-stratified binge-episode reduction data were not published in the primary papers [4]. Given that binge eating disorder has a prevalence that may be at least as high in Hispanic / Latino women as in non-Latino white women, this representation gap is clinically significant.

Population PK Analyses

Shire (now Takeda) submitted population pharmacokinetic analyses to the FDA during the lisdexamfetamine approval process. Those analyses identified body weight and urinary pH as the two most influential covariates for d-amphetamine exposure, while race and ethnicity as categorical variables did not independently predict systemic exposure after controlling for weight and pH [5]. This finding has been interpreted to mean ethnicity "doesn't matter." That interpretation is incomplete. Race and ethnicity serve as proxies for underlying biological variables like CYP2D6 genotype and dietary urinary pH. When those underlying variables are measured and included, the ethnicity signal disappears not because biology is uniform but because the proxies are absorbed into better-specified covariates.

Pharmacogenomic Mechanisms Specific to Latino Populations

The following three-layer framework organizes the pharmacogenomic considerations that are most relevant when prescribing lisdexamfetamine to a Hispanic / Latino patient.

Layer 1: Prodrug Activation (Erythrocyte Biology)

Erythrocyte peptidase activity determines how fast the prodrug converts to d-amphetamine. This layer is largely CYP-independent. Clinicians should ask about anemia, hemoglobin disorders, and recent blood loss. A patient with significantly reduced erythrocyte mass may theoretically convert lisdexamfetamine more slowly, producing a blunted peak effect. No published human trial has formally tested this relationship.

Layer 2: Amphetamine Metabolism (CYP2D6, CYP3A4)

Once d-amphetamine is circulating, CYP2D6 and, to a lesser extent, CYP3A4 handle oxidative metabolism. As noted above, CYP2D6*4 poor-metabolizer frequency is lower in many Latino subgroups than in non-Latino white populations, and gene duplication ultra-rapid-metabolizer alleles may be more common. Practical implication: clinicians who see a Latino patient reporting short duration of effect should consider CYP2D6 genotyping before simply escalating the dose, because the mechanism may be pharmacokinetic rather than pharmacodynamic. Pharmacogenomic testing through CLIA-certified laboratories is now reimbursed by some payers for patients with documented medication failures [6].

Layer 3: Renal Excretion (Urinary pH, Diet, and Carbonic Anhydrase Inhibitors)

At urinary pH 5.0, approximately 55% of a dose of amphetamine is excreted unchanged. At pH 7.5, that fraction drops to roughly 3%. Traditional Mexican and Central American diets, which are high in corn, beans, tomatoes, and citrus, tend to alkalinize urine relative to high-protein Western diets [7]. A patient eating a traditional plant-forward diet may clear d-amphetamine renally far faster than population pharmacokinetic models predict, producing lower AUC and shorter effective duration even with ultra-rapid CYP2D6 genotype eliminated as an explanation.

Clinicians rarely ask patients about urinary pH. They probably should, at least for stimulant prescriptions.

Comorbidity Context: Type 2 Diabetes and Insulin Resistance

Hispanic / Latino adults in the United States have a prevalence of type 2 diabetes of approximately 12.5%, compared with 7.5% in non-Latino white adults, per CDC surveillance data [8]. Insulin resistance is even more common than diagnosed diabetes in this population. This matters for lisdexamfetamine prescribing in two directions.

First, amphetamines suppress appetite and may reduce carbohydrate intake enough to lower blood glucose unpredictably in patients on sulfonylureas or insulin. Hypoglycemia risk is real and underappreciated in this prescribing context.

Second, lisdexamfetamine is FDA-approved for binge eating disorder, a condition that co-occurs with obesity and insulin resistance at high rates. Hispanic / Latino patients with binge eating disorder who also carry a diagnosis of type 2 diabetes or prediabetes require coordinated endocrinology and psychiatry oversight when starting lisdexamfetamine. The drug's anorexigenic effect can improve glycemic metrics, but the cardiovascular stimulant effects, tachycardia and elevated blood pressure in particular, add risk in a population already at elevated baseline cardiovascular risk.

Blood Pressure and Cardiovascular Monitoring

The American Heart Association recommends baseline and periodic cardiovascular assessment before and during stimulant treatment in all patients [9]. For Hispanic / Latino patients, who have a higher burden of hypertension, obesity, and metabolic syndrome, the monitoring schedule should not be relaxed. A resting heart rate above 100 bpm or a blood pressure above 130/80 mmHg at baseline warrants cardiology input before lisdexamfetamine is started.

Dosing Considerations for Hispanic / Latino Patients

Standard FDA-approved dosing of lisdexamfetamine begins at 30 mg once daily, with titration in 10 to 20 mg increments to a target of 50 to 70 mg/day. These ranges were derived from populations that did not specifically include or analyze Hispanic / Latino participants in powered subgroup designs.

Starting Low When Pharmacogenomic Data Are Absent

When a clinician does not have CYP2D6 genotyping results and does not know a patient's urinary pH profile, the safest approach is to start at 30 mg and titrate slowly, with four-week intervals between dose changes. This is slower than some prescribers prefer, but it captures the range of exposure that phenotypic diversity in Latino populations could produce. A patient who is a CYP2D6 poor metabolizer, even if that frequency is relatively lower in this ethnic group, can experience significant side effects at 50 mg if titration moves too quickly.

When to Order Pharmacogenomic Testing

Genotyping is worth ordering in four specific situations: (1) prior stimulant failures across two or more agents, (2) markedly short duration of effect (less than 4 hours from a 50 mg dose), (3) dose-limiting cardiovascular side effects at doses below 40 mg, and (4) a family history suggesting variant amphetamine metabolism. Several CLIA-certified panels, including GeneSight and Genomind, include CYP2D6 and report predicted phenotype as poor, intermediate, normal, or ultra-rapid. These panels do not predict urinary pH, which remains a dietary and physiologic variable.

Practical Dietary Counseling Points

Prescribers should ask patients whether they take vitamin C supplements, which acidify urine and may modestly increase amphetamine reabsorption. They should also ask about sodium bicarbonate use, which is sometimes used as an antacid in traditional home remedies and which alkalinizes urine substantially, potentially halving effective amphetamine exposure. These interactions are pharmacokinetically real and are documented in the lisdexamfetamine prescribing information [10].

Access Disparities and Systemic Underdiagnosis

Efficacy differences in Hispanic / Latino patients cannot be separated from access and diagnostic disparities. ADHD is underdiagnosed in Hispanic / Latino children relative to non-Latino white children, a pattern documented in CDC school-based surveillance [11]. This underdiagnosis means that by the time a Hispanic / Latino patient receives a lisdexamfetamine prescription, their ADHD may be more severe, their functional impairment more entrenched, and the likelihood of psychiatric comorbidities higher than in a matched non-Latino white patient who received earlier intervention.

The American Academy of Pediatrics' 2019 ADHD clinical practice guideline states: "Clinicians should recognize the potential for systemic inequities to affect access to care and diagnostic accuracy across racial and ethnic groups, and should make explicit efforts to mitigate these disparities." [12] That language, while not specific to lisdexamfetamine, applies directly to stimulant prescribing decisions.

Telehealth and Prescription Access

Telehealth platforms have improved geographic access for Hispanic / Latino patients in rural areas and in communities with few psychiatrists. DEA regulations that were relaxed during the COVID-19 public health emergency and subsequently extended through 2025 allowed prescribers to initiate Schedule II stimulants via telemedicine without an in-person visit. Those rules are again under regulatory review as of early 2025 [13]. Clinicians serving Hispanic / Latino communities through telehealth should monitor DEA policy updates closely, as any tightening of these rules will disproportionately affect populations with limited access to in-person psychiatric services.

Language, Adherence, and Perceived Efficacy

Medication adherence is a behavioral determinant of observed efficacy. Patients who do not fully understand their dosing instructions or who face cultural stigma around ADHD diagnoses may take lisdexamfetamine inconsistently, producing a pattern that looks like pharmacokinetic treatment failure but is actually adherence-related.

Hispanic / Latino families may hold cultural frameworks around mental health and medication that differ from the biomedical model. A 2019 qualitative study published in Journal of Attention Disorders found that Latino parents of children with ADHD frequently expressed concerns about stimulant dependence, medication "changing the child's personality," and distrust of pharmaceutical industry information [14]. Prescribers who do not elicit and address these concerns risk poor adherence, early discontinuation, and the false clinical conclusion that lisdexamfetamine was ineffective.

Providing patient education materials in Spanish is a baseline requirement, not an optional enhancement. Engaging community health workers (promotores de salud) as part of the care team significantly improves adherence outcomes in Hispanic / Latino populations with chronic conditions.

Monitoring Protocol for Hispanic / Latino Patients on Lisdexamfetamine

The following monitoring schedule reflects both standard FDA and AHA recommendations and the additional considerations specific to this population.

Before Starting

Obtain blood pressure and resting heart rate. Screen for personal and family history of cardiac arrhythmia, structural heart disease, and sudden death. Order a fasting glucose or HbA1c if type 2 diabetes risk factors are present (BMI <25 does not exclude insulin resistance in Latino adults, where visceral adiposity may be elevated at lower BMIs than in non-Latino white adults). Review all concurrent medications for CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) and alkalinizing agents.

First 90 Days

Reassess blood pressure and heart rate at 30 and 90 days. Use a validated ADHD symptom scale (ADHD-RS-5 or Conners) at each visit. If a patient reports duration of effect below 4 hours at a dose of 50 mg or higher, measure urine pH with a dipstick at the time of peak expected effect and consider CYP2D6 genotyping before escalating above 50 mg.

Long-Term Monitoring

Annual fasting glucose and lipid panel for patients with metabolic risk factors. Continued blood pressure surveillance per AHA stimulant guidelines. Document cultural and dietary changes that could affect urinary pH. If the patient begins a high-protein weight-loss diet (which acidifies urine), expect increased amphetamine reabsorption and potentially stronger or more prolonged stimulant effects at the same dose.